This is a preprint.
AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer's disease
- PMID: 38586011
- PMCID: PMC10996524
- DOI: 10.1101/2024.02.16.580751
AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer's disease
Update in
-
AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer's disease.J Neuroinflammation. 2024 Sep 28;21(1):245. doi: 10.1186/s12974-024-03214-4. J Neuroinflammation. 2024. PMID: 39342323 Free PMC article.
Abstract
Microglia-driven neuroinflammation plays an important role in the development of Alzheimer's disease (AD). Microglia activation is accompanied by the formation and chronic maintenance of TLR4 inflammarafts, defined as enlarged and cholesterol-rich lipid rafts serving as an assembly platform for TLR4 dimers and complexes of other inflammatory receptors. The secreted apoA-I binding protein (APOA1BP or AIBP) binds TLR4 and selectively targets cholesterol depletion machinery to TLR4 inflammaraft expressing inflammatory, but not homeostatic microglia. Here we demonstrated that amyloid-beta (Aβ) induced formation of TLR4 inflammarafts in microglia in vitro and in the brain of APP/PS1 mice. Mitochondria in Apoa1bp-/- APP/PS1 microglia were hyperbranched and cupped, which was accompanied by increased ROS and the dilated ER. The size and number of Aβ plaques and neuronal cell death were significantly increased, and the animal survival was decreased in Apoa1bp-/- APP/PS1 compared to APP/PS1 female mice. These results suggest that AIBP exerts control of TLR4 inflammarafts and mitochondrial dynamics in microglia and plays a protective role in AD associated oxidative stress and neurodegeneration.
Keywords: AIBP; Alzheimer’s disease; TLR4; inflammaraft; lipid rafts; microglia; mitochondria; neuroinflammation; oxidative stress.
Conflict of interest statement
Conflict of interest: Y.I.M., S.-H.C. and W.-K.J. are inventors listed in patent applications related to the topic of this paper. Y.I.M. is scientific co-founder of Raft Pharmaceuticals LLC. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Other authors declare that they have no competing interests.
Figures
References
-
- Lingwood D. & Simons K. Lipid Rafts As a Membrane-Organizing Principle. Science 327, 46–50 (2010). - PubMed
Publication types
Grants and funding
- R56 AG062479/AG/NIA NIH HHS/United States
- UG3 NS129684/NS/NINDS NIH HHS/United States
- P30 NS047101/NS/NINDS NIH HHS/United States
- P01 HL136275/HL/NHLBI NIH HHS/United States
- R41 AG081004/AG/NIA NIH HHS/United States
- I01 BX004848/BX/BLRD VA/United States
- IK6 BX005224/BX/BLRD VA/United States
- R01 GM138780/GM/NIGMS NIH HHS/United States
- U24 NS120055/NS/NINDS NIH HHS/United States
- R01 NS108934/NS/NINDS NIH HHS/United States
- RF1 AG062479/AG/NIA NIH HHS/United States
- R01 AG081037/AG/NIA NIH HHS/United States
- R01 AG062479/AG/NIA NIH HHS/United States
- RF1 MH129261/MH/NIMH NIH HHS/United States
- R01 EY031697/EY/NEI NIH HHS/United States
- R01 AG065549/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- R01 EY034116/EY/NEI NIH HHS/United States
- S10 OD021784/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous